Status:

COMPLETED

Detection of Barrett s Esophagus in Patients Without GERD Symptoms

Lead Sponsor:

Case Comprehensive Cancer Center

Conditions:

Barrett's Esophagus

Eligibility:

All Genders

50+ years

Phase:

NA

Brief Summary

The purpose of this study is to develop a method to detect Barrett's esophagus (BE) in individuals with a new office-based diagnostic test.

Detailed Description

This study will investigate whether using EsoCheck/EsoGuard(EC/EG) can detect BE in individuals at risk for BE who are currently not being detected and are not undergoing routine esophago-gastro-duode...

Eligibility Criteria

Inclusion

  • No known coagulopathy, no known esophageal varices.
  • No significant dysphagia or odynophagia
  • Absence of chronic GERD, defined as five or more years of heartburn or regurgitation with symptoms at least once a week when not on medications for GERD symptoms.
  • Subjects to qualify must meet criterion 3, be over age 50, and have two additional risk factors for BE (white race, central obesity defined as waist size \>35 inches for women and \>40 inches for men, male gender, current smoker or smoking history \>10 pack years, confirmed family history in at least two members with one being a first degree relative).

Exclusion

  • History of prior EGD procedure
  • Inability to provide written informed consent
  • History of weekly of more frequent heartburn or regurgitation for five or more years
  • On anti-coagulant drug(s)that cannot be temporarily discontinued or coagulopathy with international normalized ratio (INR) \> 1.5
  • Known history of esophageal varices or esophageal stricture
  • Any contraindication, as deemed inInvestigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGDprocedure,and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and/or esophageal ulceration
  • History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
  • Oropharyngeal tumor
  • History of esophageal or gastric surgery, with exception on uncomplicated surgical fundoplication procedure
  • History of myocardial infarction or cerebrovascular accident within past 6 months

Key Trial Info

Start Date :

January 5 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 25 2025

Estimated Enrollment :

132 Patients enrolled

Trial Details

Trial ID

NCT04880044

Start Date

January 5 2022

End Date

February 25 2025

Last Update

August 13 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Cleveland, Ohio, United States, 44106-5065